EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa

Andrew J Fratoni, Matthew L Gethers, David P Nicolau iD, Joseph L Kuti iD

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae048 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Andrew J Fratoni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Pseudomonas aeruginosa, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gram-negative antibiotic resistance continues to grow as a global problem due to the evolution and spread of β-lactamases. The early β-lactamase inhibitors (BLIs) are characterized by spectra limited to class A β-lactamases and ineffective against carbapenemases and most extended spectrum β-lactamases. In order to address this therapeutic need, newer BLIs were developed with the goal of treating carbapenemase producing, carbapenem resistant organisms (CRO), specifically targeting the Klebsiella pneumoniae carbapenemase (KPC). These BL/BLI combination drugs, avibactam/avibactam, meropenem/vaborbactam, and imipenem/relebactam, have proven to be indispensable tools in this effort. However, non-KPC mechanisms of resistance are rising in prevalence and increasingly challenging to treat. It is critical for clinicians to understand the unique spectra of these BL/BLIs with respect to non-KPC CRO. In Part 1of this 2-part series, we describe the non-KPC attributes of the newer BL/BLIs with a focus on utility against Enterobacterales and Pseudomonas aeruginosa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsPseudomonas aeruginosaAnti-Bacterial Agentsbeta-LactamasesHumansAzabicyclo CompoundsBacterial ProteinsEnterobacteriaceaePseudomonas InfectionsMicrobial Sensitivity Testsbeta-LactamsMeropenemKlebsiella pneumoniae

Stichwörter der Autor:innen

Pseudomonas aeruginosaEnterobacteralesavibactam/avibactamimipenem/relebactammeropenem/vaborbactam

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesAzabicyclo CompoundsBacterial Proteinscarbapenemaserelebactambeta-LactamsMeropenem

Autor:innen und Institutionen

  • Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.

ORCID-Profile: David P Nicolau, Joseph L Kuti

Zitieren

APA

Fratoni, A. J., Gethers, M. L., Nicolau, D. P., & Kuti, J. L. (2024). Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae048

Vancouver

Fratoni AJ, Gethers ML, Nicolau DP, Kuti JL. Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae048

BibTeX
@article{Fratoni2024,
  author = {Fratoni, Andrew J and Gethers, Matthew L and Nicolau, David P and Kuti, Joseph L},
  title = {Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae048}
}
Kostenlos starten →